NYSE:LLY - Eli Lilly and Stock Price, Price Target & More

$79.06 -0.69 (-0.87 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$79.06
Today's Range$78.82 - $79.91
52-Week Range$73.69 - $89.09
Volume5.42 million shs
Average Volume4.72 million shs
Market Capitalization$87.34 billion
P/E Ratio18.47
Dividend Yield2.82%
Beta0.26

About Eli Lilly and (NYSE:LLY)

Eli Lilly and logoEli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000

Debt

Debt-to-Equity Ratio0.85%
Current Ratio1.32%
Quick Ratio1.01%

Price-To-Earnings

Trailing P/E Ratio18.47
Forward P/E Ratio16.23
P/E Growth1.46

Sales & Book Value

Annual Sales$22.87 billion
Price / Sales3.79
Cash Flow$5.4903 per share
Price / Cash14.40
Book Value$10.60 per share
Price / Book7.46

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins-0.89%
Return on Equity33.01%
Return on Assets10.88%

Miscellaneous

Employees40,655
Outstanding Shares1,095,600,000

How to Become a New Pot Stock Millionaire

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, December 11th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share on Friday, March 9th. This represents a $2.25 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and's previous quarterly dividend of $0.52. View Eli Lilly and's Dividend History.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Co (NYSE:LLY) posted its quarterly earnings results on Wednesday, January, 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.08 by $0.06. The business earned $6.16 billion during the quarter, compared to analysts' expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $0.95 EPS. View Eli Lilly and's Earnings History.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Eli Lilly and.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY18 earnings guidance on Wednesday, January, 31st. The company provided earnings per share guidance of $4.81-4.91 for the period, compared to the Thomson Reuters consensus estimate of $4.67. The company issued revenue guidance of $23.0-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.

What price target have analysts set for LLY?

19 equities research analysts have issued 1 year price targets for Eli Lilly and's stock. Their predictions range from $79.00 to $115.00. On average, they anticipate Eli Lilly and's stock price to reach $93.50 in the next year. View Analyst Ratings for Eli Lilly and.

What are Wall Street analysts saying about Eli Lilly and stock?

Here are some recent quotes from research analysts about Eli Lilly and stock:
  • 1. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which underperformed in 2017, is a prudent decision in our view. However, competitive pressure on Lilly’s drugs is expected to rise this year. Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Nontheless, estimates have gone up ahead of the Q1 earnings release. Lilly has a positive record of earnings surprises in recent quarters." (4/11/2018)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)

Are investors shorting Eli Lilly and?

Eli Lilly and saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 10,533,801 shares, a decrease of 26.5% from the March 15th total of 14,330,820 shares. Based on an average trading volume of 4,479,492 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.1% of the shares of the stock are short sold.

Who are some of Eli Lilly and's key competitors?

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the folowing people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
  • Dr. Jan M. Lundberg, Exec. VP of Science & Technology and Pres of Lilly Research Laboratories (Age 64)
  • Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
  • Mr. Enrique A. Conterno, Sr. VP, Pres of Lilly Diabetes & Pres of Lilly USA (Age 51)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)

Has Eli Lilly and been receiving favorable news coverage?

News stories about LLY stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eli Lilly and earned a daily sentiment score of 0.20 on Accern's scale. They also assigned press coverage about the company an impact score of 46.82 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (5.00%). Company insiders that own Eli Lilly and stock include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $79.06.

How big of a company is Eli Lilly and?

Eli Lilly and has a market capitalization of $87.34 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly and employs 40,655 workers across the globe.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly and (LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  765 (Vote Outperform)
Underperform Votes:  592 (Vote Underperform)
Total Votes:  1,357
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eli Lilly and (NYSE:LLY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Eli Lilly and in the last 12 months. Their average twelve-month price target is $93.50, suggesting that the stock has a possible upside of 18.26%. The high price target for LLY is $115.00 and the low price target for LLY is $79.00. There are currently 8 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.582.502.502.47
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $93.50$93.3889$94.00$89.7222
Price Target Upside: 18.26% upside18.17% upside8.07% upside3.67% upside

Eli Lilly and (NYSE:LLY) Consensus Price Target History

Price Target History for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018HC WainwrightReiterated RatingBuyLowView Rating Details
4/13/2018BMO Capital MarketsUpgradeUnderperform -> Market Perform$74.00 -> $79.00LowView Rating Details
4/13/2018Jefferies GroupSet Price TargetBuy$90.00LowView Rating Details
2/26/2018JPMorgan ChaseSet Price TargetBuy$105.00MediumView Rating Details
2/2/2018Credit Suisse GroupReiterated RatingHold$80.00LowView Rating Details
2/1/2018Bank of AmericaLower Price TargetNeutral -> Neutral$88.00 -> $86.00LowView Rating Details
1/16/2018Goldman SachsDowngradeBuy -> Neutral$86.98 -> $95.00HighView Rating Details
1/5/2018ArgusUpgradeHold -> Buy$85.52 -> $115.00MediumView Rating Details
11/21/2017Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$86.00 -> $90.00N/AView Rating Details
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$92.00 -> $93.00N/AView Rating Details
10/13/2017Piper JaffrayReiterated RatingBuy$105.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetOverweight$90.00 -> $98.00N/AView Rating Details
10/4/2017CowenReiterated RatingBuy$95.00LowView Rating Details
7/26/2017UBSDowngradeHold$85.00MediumView Rating Details
7/26/2017OppenheimerDowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/17/2017Deutsche BankReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/4/2017CitigroupReiterated RatingBuy$100.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust BanksReiterated RatingBuyN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Eli Lilly and (NYSE:LLY) Earnings History and Estimates Chart

Earnings by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Earnings Estimates

2018 EPS Consensus Estimate: $4.89
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.08$1.14$1.11
Q2 20182$1.25$1.26$1.26
Q3 20182$1.17$1.26$1.22
Q4 20182$1.25$1.37$1.31

Eli Lilly and (NYSE LLY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018$1.16N/AView Earnings Details
1/31/2018Q4 2017$1.08$1.14$5.9349 billion$6.1610 billionViewN/AView Earnings Details
10/24/2017Q3 2017$1.03$1.05$5.5181 billion$5.6580 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.5985 billion$5.8243 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.2156 billion$5.2280 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
10/21/2010Q3 2010$1.15$1.21ViewN/AView Earnings Details
7/22/2010Q2 2010$1.11$1.24ViewN/AView Earnings Details
4/19/2010Q1 2010$1.11$1.18ViewN/AView Earnings Details
1/28/2010Q4 2009$0.92$0.91ViewN/AView Earnings Details
10/21/2009Q3 2009$1.02$1.20ViewN/AView Earnings Details
7/22/2009Q2 2009$1.02$1.12ViewN/AView Earnings Details
4/20/2009Q1 2009$0.99$1.20ViewN/AView Earnings Details
1/29/2009Q4 2008$1.05$1.07ViewN/AView Earnings Details
10/23/2008Q3 2008$1.01$1.04ViewN/AView Earnings Details
7/24/2008Q2 2008$0.99$0.99ViewN/AView Earnings Details
4/21/2008Q1 2008$0.95$0.92ViewN/AView Earnings Details
1/29/2008Q4 2007$0.89$0.90ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eli Lilly and (NYSE:LLY) Dividend Information

Eli Lilly and pays an annual dividend of $2.25 per share, with a dividend yield of 2.85%. LLY's most recent quarterly dividend payment was Friday, March 9. The company has grown its dividend for the last 3 consecutive years and is increasing its dividend by an average of 2.00% each year. Eli Lilly and pays out 52.57% of its earnings out as a dividend.
Most Recent Dividend:3/9/2018
Annual Dividend:$2.25
Dividend Yield:2.85%
Dividend Growth:2.00% (3 Year Average)
Payout Ratio:52.57% (Trailing 12 Months of Earnings)
46.20% (Based on This Year's Estimates)
42.53% (Based on Next Year's Estimates)
Track Record:3 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2017quarterly$0.56252.59%2/14/20182/15/20183/9/2018
10/16/2017quarterly$0.522.42%11/14/201711/15/201712/8/2017
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Eli Lilly and (NYSE LLY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 77.66%
Insider Trading History for Eli Lilly and (NYSE:LLY)
Insider Trading History for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE LLY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Susan MahonySVPSell22,544$80.09$1,805,548.9645,652View SEC Filing  
4/13/2018Susan MahonySVPSell5,165$80.14$413,923.1045,652View SEC Filing  
3/16/2018Joshua L SmileyCFOSell3,000$79.20$237,600.0020,029View SEC Filing  
3/1/2018Donald A ZakrowskiInsiderSell860$76.50$65,790.00View SEC Filing  
2/21/2018Donald A ZakrowskiInsiderSell876$77.55$67,933.804,130View SEC Filing  
2/5/2018Donald A ZakrowskiInsiderSell900$81.09$72,981.004,130View SEC Filing  
2/5/2018Jeffrey N SimmonsSVPSell9,625$81.12$780,780.00152,120View SEC Filing  
12/13/2017Lilly Endowment IncMajor ShareholderSell200,000$88.20$17,640,000.00123,084,104View SEC Filing  
12/11/2017Jeffrey N SimmonsSVPSell12,500$86.46$1,080,750.00124,522View SEC Filing  
12/4/2017Susan MahonySVPSell36,585$86.18$3,152,895.3054,885View SEC Filing  
11/10/2017Alfonso G ZuluetaSVPSell2,003$83.67$167,591.0143,580View SEC Filing  
10/4/2017Lilly Endowment IncMajor ShareholderSell205,000$86.81$17,796,050.00View SEC Filing  
9/29/2017Lilly Endowment IncMajor ShareholderSell195,000$85.14$16,602,300.00123,513,247View SEC Filing  
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00123,682,287View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00123,865,804View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00124,049,283View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00124,265,804View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00124,475,804View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.0014,041View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.0162,056View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00114,217View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00124,690,804View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00125,125,804View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.0045,583View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.6858,443View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00886View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00125,359,047View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00125,649,408View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.398,169View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.0033,504View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.3067,802View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.7694,319View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.3942,306View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.2042,110View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00125,775,804View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.081,300View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00126,020,570View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00126,220,804View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00126,442,509View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00126,808,704View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00126,963,785View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.8410,710View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00127,090,804View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.0040,600View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00127,295,910View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.003,113View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00127,481,005View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.0045,101View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00127,660,804View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.1059,690View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.7879,403View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.7436,931View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.4039,487View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.0057,101View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00127,860,804View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00128,065,804View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.0088,131View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00128,280,804View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00128,490,804View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00128,695,804View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00128,895,804View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00129,110,804View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00129,370,804View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00134,690,804View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.8332,180View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00134,920,804View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00135,130,804View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00135,320,804View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00135,520,804View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.0057,177View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eli Lilly and (NYSE LLY) News Headlines

Source:
DateHeadline
Lilly (LLY) to Report Q1 Earnings: Whats in the Cards?Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 20 at 5:09 PM
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial CancerLilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - April 20 at 5:09 PM
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 20 at 5:09 PM
Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in MigraineLilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine
finance.yahoo.com - April 20 at 5:09 PM
Eli Lilly and (LLY) Rating Reiterated by CitigroupEli Lilly and (LLY) Rating Reiterated by Citigroup
www.americanbankingnews.com - April 19 at 10:46 PM
Eli Lilly and (LLY) Price Target Raised to $90.00Eli Lilly and (LLY) Price Target Raised to $90.00
www.americanbankingnews.com - April 19 at 10:46 PM
Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drugEli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug
www.marketwatch.com - April 19 at 5:23 PM
Investors mull Gileads filgotinib in wake of Eli Lillys/Incytes baricitinibInvestors mull Gilead's filgotinib in wake of Eli Lilly's/Incyte's baricitinib
seekingalpha.com - April 19 at 5:23 PM
Eli Lillys Blockbuster Resurrection Story Has HolesEli Lilly's Blockbuster Resurrection Story Has Holes
finance.yahoo.com - April 19 at 5:23 PM
Eli Lilly and Incyte down premarket ahead on bearish outlook on Ad Com review for arthritis med baricitinibEli Lilly and Incyte down premarket ahead on bearish outlook on Ad Com review for arthritis med baricitinib
seekingalpha.com - April 19 at 8:33 AM
FDA Panel on Lilly’s Arthritis Drug Is the Next Big Test for Biotech InvestorsFDA Panel on Lilly’s Arthritis Drug Is the Next Big Test for Biotech Investors
www.bloomberg.com - April 18 at 5:31 PM
Eli Lilly and Co (LLY) Given Consensus Rating of "Buy" by BrokeragesEli Lilly and Co (LLY) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 18 at 5:30 PM
Eli Lilly ands (LLY) Buy Rating Reaffirmed at HC WainwrightEli Lilly and's (LLY) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 18 at 9:53 AM
See what the IHS Markit Score report has to say about Eli Lilly And Co.See what the IHS Markit Score report has to say about Eli Lilly And Co.
finance.yahoo.com - April 18 at 8:33 AM
Eli Lilly and Co (LLY) Forecasted to Earn Q1 2018 Earnings of $1.14 Per ShareEli Lilly and Co (LLY) Forecasted to Earn Q1 2018 Earnings of $1.14 Per Share
www.americanbankingnews.com - April 18 at 7:54 AM
2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 20252 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025
seekingalpha.com - April 17 at 5:41 PM
Insider Selling: Eli Lilly and Co (LLY) SVP Sells 5,165 Shares of StockInsider Selling: Eli Lilly and Co (LLY) SVP Sells 5,165 Shares of Stock
www.americanbankingnews.com - April 17 at 4:23 PM
Eli Lilly and Co (LLY) SVP Sells $1,805,548.96 in StockEli Lilly and Co (LLY) SVP Sells $1,805,548.96 in Stock
www.americanbankingnews.com - April 17 at 4:23 PM
Eli Lilly and Co (LLY) Short Interest Down 26.5% in MarchEli Lilly and Co (LLY) Short Interest Down 26.5% in March
www.americanbankingnews.com - April 17 at 1:59 AM
Eli Lilly and (LLY) Set to Announce Earnings on TuesdayEli Lilly and (LLY) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 17 at 1:20 AM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- AbbVie, Biostar Pharma, Bristol-Myers Squibb, and ...Quotidian Technical Highlights on Selected Drug Makers Stocks -- AbbVie, Biostar Pharma, Bristol-Myers Squibb, and ...
www.prnewswire.com - April 16 at 8:31 AM
Eli Lilly & Co. (LLY) & Boehringer Ingelheim Announces Academic Collaboration with Oxford University for Jardiance ...Eli Lilly & Co. (LLY) & Boehringer Ingelheim Announces Academic Collaboration with Oxford University for Jardiance ...
www.streetinsider.com - April 16 at 8:31 AM
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney diseaseBoehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
www.prnewswire.com - April 16 at 8:06 AM
Zacks: Analysts Anticipate Eli Lilly and Co (LLY) Will Announce Quarterly Sales of $5.50 BillionZacks: Analysts Anticipate Eli Lilly and Co (LLY) Will Announce Quarterly Sales of $5.50 Billion
www.americanbankingnews.com - April 16 at 3:44 AM
Jefferies Group Comments on Eli Lilly and Cos Q1 2018 Earnings (LLY)Jefferies Group Comments on Eli Lilly and Co's Q1 2018 Earnings (LLY)
www.americanbankingnews.com - April 16 at 1:19 AM
Leerink Swann Lowers Eli Lilly and (LLY) to Market PerformLeerink Swann Lowers Eli Lilly and (LLY) to Market Perform
www.americanbankingnews.com - April 15 at 9:29 PM
Eli Lilly and (LLY) Downgraded by UBS to "Hold"Eli Lilly and (LLY) Downgraded by UBS to "Hold"
www.americanbankingnews.com - April 15 at 8:22 PM
Eli Lilly and (LLY) Rating Reiterated by Berenberg BankEli Lilly and (LLY) Rating Reiterated by Berenberg Bank
www.americanbankingnews.com - April 15 at 12:01 PM
Zacks: Brokerages Anticipate Eli Lilly and Co (LLY) Will Announce Earnings of $1.13 Per ShareZacks: Brokerages Anticipate Eli Lilly and Co (LLY) Will Announce Earnings of $1.13 Per Share
www.americanbankingnews.com - April 14 at 11:28 AM
UPDATE: BMO Capital Upgrades Eli Lilly (LLY) to Market Perform Citing More Balanced Risk/RewardUPDATE: BMO Capital Upgrades Eli Lilly (LLY) to Market Perform Citing More Balanced Risk/Reward
www.streetinsider.com - April 13 at 5:16 PM
Eli Lillys stock rallies after BMO raises rating, price targetEli Lilly's stock rallies after BMO raises rating, price target
finance.yahoo.com - April 13 at 5:16 PM
BMOs Bearish Stance On Eli Lilly Comes To An EndBMO's Bearish Stance On Eli Lilly Comes To An End
finance.yahoo.com - April 13 at 5:16 PM
Eli Lilly and (LLY) Lifted to "Market Perform" at BMO Capital MarketsEli Lilly and (LLY) Lifted to "Market Perform" at BMO Capital Markets
www.americanbankingnews.com - April 13 at 10:37 AM
Jefferies Group Analysts Give Eli Lilly and (LLY) a $90.00 Price TargetJefferies Group Analysts Give Eli Lilly and (LLY) a $90.00 Price Target
www.americanbankingnews.com - April 13 at 10:13 AM
Global Clinical Trials Market Overview 2017-2026: Roche Group., Eli Lilly and CompanyGlobal Clinical Trials Market Overview 2017-2026: Roche Group., Eli Lilly and Company
www.marketwatch.com - April 13 at 8:43 AM
Global Auto-Injectors Market Overview 2017-2026: Antares Pharma Inc., Bayer AG, Eli Lilly and CompanyGlobal Auto-Injectors Market Overview 2017-2026: Antares Pharma Inc., Bayer AG, Eli Lilly and Company
www.marketwatch.com - April 13 at 8:43 AM
Better Buy: AbbVie Inc. vs. Eli LillyBetter Buy: AbbVie Inc. vs. Eli Lilly
finance.yahoo.com - April 13 at 8:43 AM
Eli Lilly and (LLY) Upgraded by Zacks Investment Research to "Buy"Eli Lilly and (LLY) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 11 at 7:56 AM
AbbVie's RA Candidate Meets Primary Endpoints in Phase IIIAbbVie's RA Candidate Meets Primary Endpoints in Phase III
finance.yahoo.com - April 10 at 5:16 PM
The search for new Alzheimers treatments just faced another setback — and now everything hinges on an approach thats already run into troubleThe search for new Alzheimer's treatments just faced another setback — and now everything hinges on an approach that's already run into trouble
www.businessinsider.com - April 10 at 8:49 AM
How Bristol-Myers Squibb Stock Performed in 1Q18How Bristol-Myers Squibb Stock Performed in 1Q18
finance.yahoo.com - April 10 at 8:49 AM
Eli Lilly and (LLY) Downgraded by Zacks Investment ResearchEli Lilly and (LLY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM
SunTrust Banks Brokers Increase Earnings Estimates for Eli Lilly and Co (LLY)SunTrust Banks Brokers Increase Earnings Estimates for Eli Lilly and Co (LLY)
www.americanbankingnews.com - April 9 at 2:32 AM
Eli Lilly and (LLY) Rating Reiterated by CowenEli Lilly and (LLY) Rating Reiterated by Cowen
www.americanbankingnews.com - April 7 at 11:00 PM
Better Buy: Eli Lilly and Co. vs. GlaxoSmithKlineBetter Buy: Eli Lilly and Co. vs. GlaxoSmithKline
finance.yahoo.com - April 7 at 4:18 PM
Active-Investors: Wired News - Eli Lillys Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall SurvivalActive-Investors: Wired News - Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival
www.finanznachrichten.de - April 6 at 8:47 AM
Wired News – Eli Lillys Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall SurvivalWired News – Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival
finance.yahoo.com - April 6 at 8:47 AM
SunTrust Banks Analysts Increase Earnings Estimates for Eli Lilly and Co (LLY)SunTrust Banks Analysts Increase Earnings Estimates for Eli Lilly and Co (LLY)
www.americanbankingnews.com - April 6 at 8:23 AM
Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick FactsEli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts
www.nasdaq.com - April 5 at 10:36 AM
The case for Acadia PharmaceuticalsThe case for Acadia Pharmaceuticals
www.fool.com - April 5 at 10:36 AM

SEC Filings

Eli Lilly and (NYSE:LLY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eli Lilly and (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eli Lilly and (NYSE LLY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.